Reader Doug Faison writes in with an important thought about the recent court decision affirming the right of self—preservation and allowing certain terminal patients to take experimental drugs

One point that may have been missed in the recent AT article "Preserving Self—Preservation" is the ability of the family to sue the drug manufacturer should the experimental drug not actually save the critically ill person, or worse cause the maiming or early demise because of previously unforeseen interactions.  With the Court ruling forcing the availability of yet—to—be—proven compounds, a whole new revenue stream is now open to the unscrupulous attorney, reducing the ability and desire of the drug manufacturers to seek new cures.